Ethyl pyruvate diminishes the inflammatory response to lipopolysaccharide infusion in horses.

Summary

# Editorial Summary: Ethyl Pyruvate as an Anti-inflammatory Agent in Equine Endotoxaemia Endotoxaemia represents a significant complication in equine colic cases, driving mortality through uncontrolled inflammatory cascade activation; whilst several therapeutic approaches exist, their efficacy remains limited, prompting investigation into novel interventions. Researchers administered ethyl pyruvate (EP)—a small-molecule compound with demonstrated anti-inflammatory properties in other species—to horses receiving lipopolysaccharide (LPS) infusion to model septic conditions, measuring circulating cytokine concentrations and inflammatory markers over a defined period. EP treatment significantly attenuated the proinflammatory response, reducing key markers of systemic inflammation compared with placebo controls, suggesting a genuine modulation of the endotoxic cascade rather than merely masking clinical signs. For practitioners managing colic cases complicated by endotoxaemia or sepsis, these findings indicate EP warrants further clinical evaluation as an adjunctive therapeutic tool, potentially improving outcomes in horses where conventional anti-inflammatory protocols have proved insufficient. Given that intestinal translocation of gram-negative bacteria and subsequent LPS release remains a critical pathway in colic-associated mortality, any agent capable of dampening the inflammatory sequelae without systemic toxicity represents a valuable addition to the therapeutic arsenal.

Read the full abstract on PubMed

Key Findings

• •Ethyl pyruvate is an anti-inflammatory agent that modulates proinflammatory cytokine expression
• •EP improved survival and organ function in sepsis and gastrointestinal injury models in rodents and swine
• •Therapeutic efficacy of EP in endotoxaemic horses requires investigation

Conditions Studied